3 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
Follow Focal Segmental Glomerulosclerosis: new trials by email Literature Review of Focal Segmental Glomerulosclerosis trials Research Report on Focal Segmental Glomerulosclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) VB119 - Minimal Change Disease, Focal Segmental Glomerulosclerosis | Phase 2 | Terminated | Tenet Medicines | 1 | 2022-05-03 | 2024-04-22 |
| A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome CCX140-B - Focal Segmental Glomerulosclerosis | Phase 2 | Terminated | Amgen | 5 | 2018-10-01 | 2025-03-17 |
| Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis Voclosporin - Focal Segmental Glomerulosclerosis | Phase 2 | Terminated | Aurinia Pharmaceuticals Inc. | 5 | 2018-06-21 | 2021-09-16 |
Glomerulosclerosis, Focal Segmental (3) · Nephrosis, Lipoid (1) · Proteinuria (1)
Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Glomerulonephritis (3) · Kidney Diseases (3) · Male Urogenital Diseases (3) · Nephritis (3) · Urogenital Diseases (3) · Urologic Diseases (3) · Nephrosis (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Urination Disorders (1) · Urological Manifestations (1)
CCX140-B (1) · voclosporin (1)
Amgen (1) · Aurinia Pharmaceuticals Inc. (1) · Tenet Medicines (1)
United States (3) · Dominican Republic (1)